171 related articles for article (PubMed ID: 27941187)
1. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland.
Borecka R; Lauterbach R; Helwich E
Dev Period Med; 2016; 20(3):181-190. PubMed ID: 27941187
[TBL] [Abstract][Full Text] [Related]
2. Compliance with the RSV immunoprophylaxis dosing schedule in the Polish registry for palivizumab (2008-2014).
Borecka R; Lauterbach R
Dev Period Med; 2018; 22(4):308-314. PubMed ID: 30636227
[TBL] [Abstract][Full Text] [Related]
3. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
5. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
7. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
Diehl JL; Daw JR; Coley KC; Rayburg R
J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
[TBL] [Abstract][Full Text] [Related]
8. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
9. Palivizumab compliance in congenital heart disease patients: factors related to compliance and altered lower respiratory tract infection viruses after palivizumab prophylaxis.
Sel K; Aypar E; Dönmez YN; Aliyev E; Aykan HH; Karagöz T; Alehan D
Cardiol Young; 2020 Jun; 30(6):818-821. PubMed ID: 32425145
[TBL] [Abstract][Full Text] [Related]
10. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.
Claydon J; Sur A; Callejas A; Ladd M; Kwan E; Taylor R; Turvey SE; Solimano A; Lavoie PM; Marr N
PLoS One; 2017; 12(4):e0176152. PubMed ID: 28437470
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
[TBL] [Abstract][Full Text] [Related]
13. A 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: how can compliance be improved?
Pignotti MS; Catarzi S; Donzelli G
J Matern Fetal Neonatal Med; 2006 Apr; 19(4):221-4. PubMed ID: 16854695
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
Lundeen K; Pfeiffenberger T; Jacobson Vann J; O'Brien T; Sampson C; Wegner S
J Manag Care Pharm; 2013 Mar; 19(2):115-24. PubMed ID: 23461427
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).
Paes B; Mitchell I; Li A; Lanctôt KL;
Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2703-11. PubMed ID: 22546928
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
17. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
19. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
Paes B; Saleem M; Kim D; Lanctôt KL; Mitchell I
Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1561-1568. PubMed ID: 31119575
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
Piñeros JG; De la Hoz-Valle J; Galvis C; Celis A; Ovalle O; Sandoval CC; Orrego J; Vides S; Rojas I; Bustamante H; Gallón C; Mesa JA
J Infect Dev Ctries; 2021 Nov; 15(11):1708-1713. PubMed ID: 34898500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
